About Enhancer
| Enhancer ID: | E_02286 |
| Species: | Homo sapiens |
| Position : | chr1:214150511-214151337   |
| Year: | 2015 |
| Title: | GATA2 is required for lymphatic vessel valve development and maintenance. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | Lymphedema |
| PMID: | 26214525 |
| MONDO: | MONDO:0019297 |
| Tissue: | lymphatic vessel |
| Tissue Ontology ID: | UBERON:0001473 |
| Cell Source: | K-562 |
| CVCL ID: | CVCL_0004 |
| Experiment Type: | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| High Throughput Method: | ChIP-seq |
| Low Throughput Method: | Luciferase reporter assay; Reporter assay; ChIP-qPCR/ChIP |
About Target Gene
| Target gene : | PROX1 |
About TF
| TF name : | NFATC1 |
About Regulatory State
| Regulatory State : | Active |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| NFATC1 | AP-1 transcription factor network | pid | 71 |
| NFATC1 | BCR signaling pathway | pid | 70 |
| NFATC1 | Ca2+ pathway | reactome | 62 |
| NFATC1 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | pid | 50 |
| NFATC1 | Calcium signaling in the CD4+ TCR pathway | pid | 29 |
| NFATC1 | CLEC7A (Dectin-1) induces NFAT activation | reactome | 13 |
| NFATC1 | Downstream signaling in naïve CD8+ T cells | pid | 69 |
| NFATC1 | FCERI mediated Ca+2 mobilization | reactome | 41 |
| NFATC1 | Glucocorticoid receptor regulatory network | pid | 85 |
| NFATC1 | Inflammation mediated by chemokine and cytokine signaling pathway | panther | 189 |
| NFATC1 | RANKL | netpath | 84 |
| NFATC1 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | pid | 54 |
| NFATC1 | Signaling by Wnt | reactome | 10 |
| NFATC1 | TCR | netpath | 261 |
| NFATC1 | Validated transcriptional targets of AP1 family members Fra1 and Fra2 | pid | 37 |
| NFATC1 | Wnt signaling pathway | panther | 250 |
| NFATC1 | Wnt signaling pathway | kegg | 135 |
| NFATC1 | Axon guidance | kegg | 126 |
| NFATC1 | VEGF signaling pathway | kegg | 70 |
| NFATC1 | Natural killer cell mediated cytotoxicity | kegg | 125 |
| NFATC1 | T cell receptor signaling pathway | kegg | 105 |
| NFATC1 | B cell receptor signaling pathway | kegg | 70 |
| NFATC1 | Hs_VEGFA-VEGFR2_Signaling_Pathway_WP3888_90000 | wikipathways | 153 |
| NFATC1 | Hs_TLR4_Signaling_and_Tolerance_WP3851_90114 | wikipathways | 8 |
| NFATC1 | Hs_T-Cell_antigen_Receptor_(TCR)_Signaling_Pathway_WP69_89937 | wikipathways | 60 |
| NFATC1 | Hs_RANKL-RANK_(Receptor_activator_of_NFKB_(ligand))_Signaling_Pathway_WP2018_90016 | wikipathways | 26 |
Enhancer Associated Network
Overlapping Enhancers (hg19)
11 found
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_02200 | chr1:214150511-214151337 | dermis | endothelial cell | lymphedema |
| E_02271 | chr1:214150511-214151337 | dermis | endothelial cell | lymphedema |
| E_02272 | chr1:214150511-214151337 | dermis | endothelial cell | lymphedema |
| E_02284 | chr1:214150511-214151337 | lymphatic vessel | NA | Lymphedema |
| E_02285 | chr1:214150511-214151337 | lymphatic vessel | NA | Lymphedema |
| E_02266 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |
| E_02273 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |
| E_02274 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |
| E_02275 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |
| E_02276 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |
| E_02277 | chr1:214150857-214151185 | lymphatic vessel | endothelial cell | acute myeloid leukemia |
Expression of Target Genes for the Enhancer